DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Sickle Cell Disease: After Years of Neglect Some Promise for Sufferers
It’s Black History Month, when the nation commemorates the many achievements and contributions of African Americans.
It’s also a time to reflect on certain health issues with significant mortality and morbidity that disproportionately afflict African Americans.
Sickle cell disease (SCD) is one such health problem. SCD is a group of congenital red blood cell disorders, named sickle cell for the crescent shape of red blood cells. SCD alters the structure of hemoglobin, the molecule in red blood cells that delivers oxygen to organs and tissue throughout the body. The most common SCD disorder type is sickle cell anemia.
SCD affects millions of people worldwide. In the U.S., approximately 100,000 individuals are living with the congenital disease. The disease predominantly impacts people of sub-Saharan African descent.
SCD causes significant morbidity, including severe pain, anemia, organ damage, and infections. The disease also leads to premature mortality.
Related Content
-
news & eventsPhase 3 Trial Recruiting to Test Rivipansel for Vaso-Occlusive Crisis in SCDGlycoMimetics, in collaboration with Pfi...
-
news & eventsFDA agrees accelerated approval pathway for GBT’s voxelotorGlobal Blood Therapeutics, Inc. ...
-
education & researchRealizing Effectiveness Across Continents With Hydroxyurea: Enrollment and Baseline Characteristics of the Multicent...Despite its well-described safety and ef...
-
education & researchInitial results from a cohort in a phase 2a study (GBT440-007) evaluating adolescents with sickle cell disease treat...Background: Sickle cell disease (SCD), ...
-
news & eventsFirst Sickle Cell Patient Dosed in Phase 2a of IMR-687This morning, Imara Inc. announced that ...
-
news & eventsSpectra Optia Device Save Way to Treat Sickle Cell While Using Less Blood Cell Packs, Study FindsThe blood-separation device Spectra Opti...
-
news & eventsFDA grants CRISPR gene therapy fast track designation for sickle cell diseaseThe FDA granted fast track designation t...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.